Ultime notizie per International Land (OTC:ILAL) Azioni

International Land Alliance Inc is a residential land development company with target properties located in the Baja California, Norte region of Mexico. Its activities include purchasing properties, obtaining zoning and other entitlements required to subdivide the properties into residential and commercial building plots, securing financing for the purchase of the plots, improving the property's infrastructure and amenities, and selling the plots to homebuyers, retirees, investors, and commercial developers. The Company's real estate portfolio includes Oasis Park Resort, Valle Divino in Ensenada, Plaza Bajamar Resort which is part of Bajamar Oceanfront hotel and Golf Resort, Emerald Grove Estates in Southern California, and lastly Rancho Costa Verde, on Baja California's east coast.

INTERNATIONAL LAND ALLICE by International Land Alliance Inc.

International Land Alliance Inc

WIIM

SBUX

Starbucks shares are trading higher following reports suggesting the company has drawn interest from potential investors regarding its China business.

TD Cowen analyst Kyle Bauser initiates coverage on Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy rating and announces Price Target of $65.

News

Price Target

Initiation

Analyst Ratings

TECH

TD Cowen Initiates Coverage On Bio-Techne with Buy Rating, Announces Price Target of $65

Triple Flag Precious Metals Corp. (with its subsidiaries, "Triple Flag" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TFPM#TSX">TFPM</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFPM#NYSE">TFPM</a>) announced record revenue of US$94.1 million for the second quarter of 2025 from quarterly metal sales of 28,682 gold equivalent ounces ("GEOs"). All dollar amounts are expressed in US dollars, unless otherwise noted.
"Triple Flag achieved another quarter of record revenue, driven by record performance from Northparkes. Following a strong first half of the year, we remain on track to deliver our 2025 GEOs guidance of 105,000 to 115,000 ounces," commented Sheldon Vanderkooy, CEO. "We expect our transaction with Orogen Royalties to close imminently, which will result in Triple Flag's acquisition of a 1.0% NSR royalty on AngloGold Ashanti's Arthur gold project1 in Nevada. Arthur is a tier one gold asset that we expect will drive significant additional long-term GEOs growth."

TFPM

TSX:TFPM

Triple Flag Reports Q2 Revenue Of $94.1M From Quarterly Metal Sales Of 28,682 Gold Equivalent Ounces

Ripple Selects BNY Mellon As Primary Custodian For Ripple USD (RLUSD) Reserves To Support Institutional-Scale Stablecoin Adoption

Primis, the video discovery platform for publishers and part of the McCann and IPG network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>), has signed an exclusive partnership with Absolute Sports, the global digital media group behind <a href="http://sportskeeda.com/">Sportskeeda.com</a>,&nbsp;and other leading brands. With over 80 million monthly users and reach across 150+ countries, Absolute Sports is a leading force in global digital sports media.
&nbsp;
As part of the partnership, the&nbsp;Primis online video player has been fully integrated across all Absolute Sports websites. This lightweight video technology fits seamlessly within editorial environments, surfacing original video content in context. The result is a non-intrusive viewing experience that encourages users to keep exploring. It guides them naturally from one story to the next and creates a self-contained discovery journey that keeps audiences immersed in the brand experience.

IPG-Owned Primis Teams Up With Sportskeeda Parent to Power Video Discovery for 80M Global Sports Fans

Contracts

GILT

Gilat Commercial Division Receives Over $22M In Orders From Satellite Operators, Scheduled For Delivery Over Next 12 Months

<ul>
<li>NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile</li>
<li>No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits</li>
</ul>

NMRA

Neumora Therapeutics Begins Phase 1 Clinical Trial Of NMRA-861, A Selective M4 Positive Allosteric Modulator For Schizophrenia

Autozi Receives Nasdaq Notification For Failing To Meet $50M Market Value Requirement; Has Until Jan 5, 2026 To Regain Compliance

TD Cowen analyst Bill Katz downgrades LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) from Buy to Hold and lowers the price target from $406 to $403.

Downgrades

LPLA

TD Cowen Downgrades LPL Finl Hldgs to Hold, Lowers Price Target to $403

Through the agreement, Redwire and SpaceData will focus on the following areas of collaboration:
<ul>
<li>Identify opportunities to integrate SpaceData into Redwire's digital ecosystem to support current and future missions to the International Space Station (ISS);</li>
<li>Explore combined solutions to pursue opportunities to support NASA Commercial Low Earth Orbit (LEO) Destination utilization components, systems, and software;</li>
<li>Explore future collaborations for Cislunar, Lunar and Deep Space missions and services; and</li>
<li>Redwire will look to leverage SpaceData's artificial intelligence (AI) for space and robotics capabilities.</li>
</ul>

General

Redwire Signs MoU With Japanese Startup SpaceData For Collaborations On Artificial Intelligence And Digital Engineering Systems

Parsons Subsidiary SealingTech Teams Up With NCS To Expand Cyber Hunt Kit Production For Defense Agencies

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4464805-1&amp;h=3813736257&amp;u=https%3A%2F%2Fwww.galaxy.com%2F&amp;a=Galaxy+Digital+Inc.">Galaxy Digital Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#NASDAQ">GLXY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#TSX">GLXY</a>)&nbsp;announced today that it has integrated with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4464805-1&amp;h=3593130843&amp;u=https%3A%2F%2Fwww.fireblocks.com%2F&amp;a=Fireblocks">Fireblocks</a>, the leading digital asset and payments infrastructure platform for moving, storing, and issuing digital assets. This collaboration significantly broadens access to Galaxy's staking services by connecting to Fireblocks' global network of institutions that rely on its battle-tested digital asset security platform.
&nbsp;
With this integration, Galaxy's staking services are now natively accessible to more than 2,000 of the world's largest financial institutions that use Fireblocks to securely manage digital assets. Clients can stake digital assets directly from their Fireblocks vaults – without moving assets off-platform – while leveraging Galaxy's high-performance, globally-distributed validator infrastructure.
This collaboration allows institutions to participate in secure, scalable staking while exploring advanced strategies that tap into Galaxy's integrated trading and lending solutions, transforming passive staking into a capital-efficient, reward-generating strategy.

GLXY

TSX:GLXY

Galaxy Digital Opens Staking Access to 2,000+ Institutions Through Fireblocks Integration

SMTK

Smartkem Enters Preliminary Joint Development Agreement With Manz Asia To Co-Develop Dielectric Ink Solutions For AI Chip Packaging

Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today&nbsp;announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, and the appointment of, the Company's new CEO. The Arvinas Board of Directors has begun a search for a new CEO, and Dr. Houston will remain Chairperson of Arvinas' Board of Directors upon retiring as President and CEO.
"On behalf of the Arvinas Board of Directors, I sincerely thank John for his exceptional leadership and significant contributions to Arvinas over the past 8 years and his commitment to a smooth transition as we identify his successor," said Briggs Morrison, M.D., Arvinas Board Member and Lead Independent Director. "John has guided Arvinas through a substantial number of ‘firsts' for PROTACs in the industry, from the first to enter the clinic to the first positive pivotal Phase 3 trial and the first new drug application. John and Arvinas have turned targeted protein degradation into a well-known modality across several therapeutic areas. Due to his efforts, the Company is well positioned to benefit many patients in the years to come. As we undertake the process of identifying a new CEO, the Board is committed to conducting a thoughtful search to ensure continued strong leadership. We look forward to continuing our work with John in his capacity as Chairperson."
With more than 35 years of experience in the pharmaceutical and biotech industries, Dr. Houston joined Arvinas in January 2017 as President of Research and Development and Chief Scientific Officer responsible for leading the discovery, translational, and early clinical development research efforts. In September 2017, Dr. Houston was appointed President and CEO, and in 2023 he was named Arvinas' Chairperson.
During his tenure as CEO, Dr. Houston has been instrumental in Arvinas' success moving six programs into the clinic, reporting the results of the first positive pivotal Phase 3 trial for a PROTAC, and reporting for the first time that an orally administered PROTAC can achieve pharmacodynamic activity in the central nervous system.
"It has been an honor to lead Arvinas alongside incredibly talented colleagues and a supportive Board of Directors," said Dr. Houston. "I look forward to remaining a part of Arvinas as Chairperson and I'm confident in the Company's ability to improve the lives of patients with serious diseases through our revolutionary PROTAC protein degradation platform. From initiating the first oral PROTAC degrader in clinical trials to delivering positive topline results, it is evident that Arvinas has and will continue to push the boundaries of what's possible."

Management

ARVN

Arvinas Begins CEO Search as Longtime Leader John Houston Plans Exit From Top Role, Will Stay On as Board Chair

– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH Dispensed applicator units in Q2 2025 –
– Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts –

VRCA

Verrica Reports Record 13,434 YCANTH Applicator Units Dispensed In Q2 2025, Marking 32.8% Sequential Growth

B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) ("B. Riley" or the "Company"), a diversified financial services company, today announced that it has entered into an amendment to its senior secured credit agreement ("Term Loan Facility") with funds managed by Oaktree Capital Management, L.P. ("Oaktree").
The amended Term Loan Facility provides incremental flexibility, including: a new investment basket that enables an incremental $100m to facilitate transactions using B. Riley Financial's balance sheet; a $30 million investment basket for parent company investments upsized from $20 million; and the ability to deploy up to $25 million of cash to reduce other indebtedness, including through the potential repurchase of the Company's unsecured notes.

Financing

RILY

B. Riley Financial Enters Amendment To Senior Credit Facility With Oaktree; Amendment Increases Operational Flexibility, Outstanding Balance Reduced To $62.5M

TD Cowen analyst John Blackledge maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $700 to $800.

TD Cowen Maintains Buy on Meta Platforms, Raises Price Target to $800

SES AI Unveils Deep Space In MU-0.5, Enabling Senior Scientist-Level Battery R&D In Minutes With Agentic AI

KB801 is a redosable eye drop gene therapy in development for the treatment of NK, a degenerative corneal disease characterized by damage or loss of function in the neurons innervating the eye leading to corneal epithelial defects, ulcers, and perforation. Left untreated, NK can result in severe vision loss. Although NK is a rare disease with an estimated prevalence in the range of 10 to 50 cases per 100,000, claims data analyses suggest awareness and diagnosis rates are on the rise in the United States. Based on available claims data, an estimated 68,000 patients in the United States had a NK claim in 2024, up over 115% from 31,000 patients with a NK claim in 2020.

Biotech

Health Care

KRYS

Krystal Biotech Has Dosed The First Patient In Its Phase 1/2 EMERALD-1 Trial Evaluating KB801 For Neurotrophic Keratitis

ALMU

Aeluma Expands Defense And Aerospace Footprint WIth NASA and Navy Contracts To Develop Quantum And Imaging Solutions

Press Releases

International Land Alliance Announces Approval of Plans and Final Site Location for Condotel at Oasis Park

Janover Licenses its AI Tech to International Land Alliance, Bringing Cutting Edge AI Technology to their Operations

International Land Alliance Announces Second Quarter Results

International Land Alliance Reports Sales at Rancho Costa Verde and Oasis Park from September 7 Sales Event

International Land Alliance Announces Addition to Construction Division

International Land Alliance Announces First Home Construction at Oasis Park

International Land Alliance Announces Third Quarter Results

International Land Alliance Achieves Profitability for First Time in 2024

International Land Alliance Updates Construction at Oasis Park

International Land Alliance FY24 Audit Report Confirms Record Revenues Reported in March

ILAL

JNVR

International Land

Comments

International Land

Notizie

Ultime notizie per International Land (OTC:ILAL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO